| 
			  
			  
			
  
			by April McCarthy 
			February 3, 2014 
			from
			
			PreventDisease Website 
			
			Spanish version 
			  
			  
			  
				
					
						| 
						April McCarthy is a 
						community journalist playing an active role reporting 
						and analyzing world events to advance our health and 
						eco-friendly initiatives. |  
			
 
			
 It takes no more than 100 seconds for the body's immune cells to 
			identify and kill a cancer cell. Immune cells undergo ‘spontaneous’ 
			changes on a daily basis that could lead to cancers if not for the 
			diligent surveillance of our immune system, Melbourne scientists 
			have found.
 
 
 
			 
			  
			A research team from the
			
			Walter and Eliza Hall Institute found 
			that the immune system was responsible for eliminating 
			potentially cancerous immune B cells in their early stages, 
			before they developed into B-cell lymphomas (also known as 
			non-Hodgkin's lymphomas).
 
			  
			The results of the study were
			
			published today in the journal 
			Nature Medicine.
 The immune system's basic task is to recognize "self" (the body's 
			own cells) and "nonself" (an antigen - a virus, fungus, bacterium, 
			or any piece of foreign tissue, as well as some toxins). To deal 
			with nonself or antigens, the system manufactures specialized cells 
			- white blood cells - to recognize infiltrators and eliminate them. 
			We all come into the world with some innate immunity.
 
			  
			As we interact with our environment, the 
			immune system becomes more adept at protecting us. This is called 
			acquired immunity.
 Many mature white blood cells are highly specialized. The so-called 
			T lymphocytes (T stands for thymus-derived) have various functions, 
			among them switching on various aspects of the immune response, and 
			then (equally important) switching them off. Another lymphocyte, the 
			B cell, manufactures antibodies.
 
			  
			A larger kind of white cell, the 
			scavenger called the phagocyte (most notably the macrophage), eats 
			up all sorts of debris in tissue and the bloodstream, and alerts 
			certain T cells to the presence of antigens. 
				
				''The T-cells basically detect the 
				enemy and then throw grenades at the cancer cell until it blows 
				up,'' said immunologist Misty Jenkins from the Peter MacCallum 
				Cancer Centre.  
			T-cells are a type of white blood cell 
			that are key to the body's immune response.  
			  
			Normally when a T-cell kills the target, 
			the only way you would know that the target has been hit or killed 
			is when it physically starts to die.
 However the B-cells bind to a specific antigen and antibodies 
			against these antigens, thus performing the role of 
			antigen-presenting cells (APCs), and to develop into memory B 
			cells after activation by antigen interaction.
 
 This immune surveillance accounts for what researchers at the 
			institute call the 'surprising rarity' of B-cell lymphomas in the 
			population, given how often these spontaneous changes occur.
 
			  
			The discovery could lead to the 
			development of an early-warning test that identifies patients at 
			high risk of developing B-cell lymphomas, enabling proactive 
			treatment to prevent tumors from growing.
 All B-cells, whether healthy or cancerous, have on their surfaces a 
			proteins. To treat patients with the disease, the researchers need 
			to find ways to reprogram their T-cells to find the proteins and 
			attack B-cells carrying it.
 
 Dr Axel Kallies, Associate Professor David Tarlinton, 
			Dr Stephen Nutt and colleagues made the discovery while 
			investigating the development of B-cell lymphomas.
 
 Dr Kallies said the discovery provided an answer to why B-cell 
			lymphomas occur in the population less frequently than expected.
 
				
				"Each and every one of us has 
				spontaneous mutations in our immune B cells that occur as a 
				result of their normal function," Dr Kallies said. "It is then 
				somewhat of a paradox that B cell lymphoma is not more common in 
				the population.
 "Our finding that immune surveillance by T cells enables early 
				detection and elimination of these cancerous and pre-cancerous 
				cells provides an answer to this puzzle, and proves that immune 
				surveillance is essential to preventing the development of this 
				blood cancer."
 
			B-cell lymphoma is the most common blood 
			cancer in Australia, with approximately 2800 people diagnosed each 
			year and patients with a weakened immune system are at a higher risk 
			of developing the disease.
 The research team made the discovery while investigating how B cells 
			change when lymphoma develops.
 
				
				"As part of the research, we 
				'disabled' the T cells to suppress the immune system and, to our 
				surprise, found that lymphoma developed in a matter of weeks, 
				where it would normally take years," Dr Kallies said. 
				   
				"It seems that our immune system is 
				better equipped than we imagined to identify and eliminate 
				cancerous B cells, a process that is driven by the immune T 
				cells in our body." 
			Associate Professor Tarlinton said the 
			research would enable scientists to identify pre-cancerous cells in 
			the initial stages of their development, enabling early intervention 
			for patients at risk of developing B-cell lymphoma. 
				
				"In the majority of patients, the 
				first sign that something is wrong is finding an established 
				tumour, which in many cases is difficult to treat" Associate 
				Professor Tarlinton said.    
				"Now that we know B-cell lymphoma is 
				suppressed by the immune system, we could use this information 
				to develop a diagnostic test that identifies people in early 
				stages of this disease, before tumors develop and they progress 
				to cancer. There are already therapies that could remove these 
				'aberrant' B cells in at-risk patients, so once a test is 
				developed it can be rapidly moved towards clinical use." 
			   
			 |